Variation in the use of diuretic therapy for infants with bronchopulmonary dysplasia
- PMID: 23478874
- PMCID: PMC3608485
- DOI: 10.1542/peds.2012-1835
Variation in the use of diuretic therapy for infants with bronchopulmonary dysplasia
Abstract
Objectives: To determine (1) between-hospital variation in diuretic use for infants with bronchopulmonary dysplasia (BPD), including hospital-specific treatment frequency, treatment duration, and percentage of infants receiving short (≤5 consecutive days) versus longer (>5 days) courses, and to determine (2) demographic and clinical variables associated with diuretic administration.
Methods: A retrospective cohort study was conducted with the use of the Pediatric Health Information System to determine between-hospital variation in diuretic utilization patterns (primary outcome) and variables associated with diuretic use among <29-week-gestation infants with evolving BPD at age 28 days who were discharged between January 2007 and June 2011.
Results: During the 54-month study period, 1429 infants within 35 hospitals met the inclusion criteria for BPD at age 28 days, with 1222 (86%) receiving diuretic therapy for a median of 9 days (25th-75th percentile: 2-33 days). Short courses were administered to 1203 (83%) infants, and 570 (40%) infants received treatment for >5 consecutive days. Furosemide was the most widely prescribed diuretic (1218 infants; 85%), although chlorothiazide had the longest median duration of use (21 days; 25th-75th percentile: 8-46 days). The range of infants receiving a diuretic course of >5 days duration varied by hospital from 4% to 86%, with wide between-hospital variation even after adjustment for confounding variables.
Conclusions: The frequency of diuretic administration to infants with BPD at US children's hospitals, as well as the specific diuretic regimen used, varies markedly by institution. Safety and effectiveness research of long-term diuretic therapy for BPD patients is needed to develop evidence-based recommendations.
Figures
Similar articles
-
Sildenafil Treatment of Infants With Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension.Hosp Pediatr. 2016 Jan;6(1):27-33. doi: 10.1542/hpeds.2015-0076. Epub 2015 Jan 1. Hosp Pediatr. 2016. PMID: 26666265
-
Loop Diuretics in Severe Bronchopulmonary Dysplasia: Cumulative Use and Associations with Mortality and Age at Discharge.J Pediatr. 2021 Apr;231:43-49.e3. doi: 10.1016/j.jpeds.2020.10.073. Epub 2020 Nov 3. J Pediatr. 2021. PMID: 33152371 Free PMC article.
-
Diuretic exposure in premature infants from 1997 to 2011.Am J Perinatol. 2015 Jan;32(1):49-56. doi: 10.1055/s-0034-1373845. Epub 2014 May 6. Am J Perinatol. 2015. PMID: 24801161 Free PMC article.
-
Aerosolized diuretics for preterm infants with (or developing) chronic lung disease.Cochrane Database Syst Rev. 2000;(2):CD001694. doi: 10.1002/14651858.CD001694. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2001;(2):CD001694. doi: 10.1002/14651858.CD001694. PMID: 10796271 Updated. Review.
-
Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease.Cochrane Database Syst Rev. 2000;(3):CD001817. doi: 10.1002/14651858.CD001817. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2002;(1):CD001817. doi: 10.1002/14651858.CD001817. PMID: 10908511 Updated. Review.
Cited by
-
Association of furosemide versus chlorothiazide exposures with serum sodium, potassium, and chloride among infants with bronchopulmonary dysplasia.J Perinatol. 2024 Nov 5. doi: 10.1038/s41372-024-02159-z. Online ahead of print. J Perinatol. 2024. PMID: 39501014
-
Strategies for the prevention of bronchopulmonary dysplasia.Front Pediatr. 2024 Jul 24;12:1439265. doi: 10.3389/fped.2024.1439265. eCollection 2024. Front Pediatr. 2024. PMID: 39114855 Free PMC article. Review.
-
Diuretic drug utilization in neonates: a French prescription database analysis.Front Pharmacol. 2024 Mar 13;15:1358761. doi: 10.3389/fphar.2024.1358761. eCollection 2024. Front Pharmacol. 2024. PMID: 38545552 Free PMC article.
-
Estimating the effect of diuretics and inhaled corticosteroids for evolving bronchopulmonary dysplasia in preterm infants.Paediatr Perinat Epidemiol. 2024 Aug;38(6):495-504. doi: 10.1111/ppe.13038. Epub 2024 Jan 8. Paediatr Perinat Epidemiol. 2024. PMID: 38192005
-
Bronchopulmonary Dysplasia: Ongoing Challenges from Definitions to Clinical Care.J Clin Med. 2023 Jun 5;12(11):3864. doi: 10.3390/jcm12113864. J Clin Med. 2023. PMID: 37298058 Free PMC article.
References
-
- Kao LC, Warburton D, Sargent CW, Platzker ACG, Keens TG. Furosemide acutely decreases airways resistance in chronic bronchopulmonary dysplasia. J Pediatr. 1983;103(4):624–629 - PubMed
-
- Stewart AL, Brion LP. Routine use of diuretics in very-low birth-weight infants in the absence of supporting evidence. J Perinatol. 2011;31(10):633–634 - PubMed
-
- Walsh MC, Szefler S, Davis J, et al. . Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics. 2006;117(3 pt 2 suppl 1):S52–S56 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
